Fangda represented WuXi Biologics (Cayman) Inc. and its substantial shareholder in the placing of US$510 million existing shares
Tell others about this press release
The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.
Fangda Partners represented WuXi Biologics (Cayman) Inc. (HK stock code: 2269) (the “Company”) and its substantial shareholder, WuXi Biologics Holdings Limited (“BH”), in the placing of 56,000,000 existing shares of the Company held by BH at a share price of HK$71.00 each involving a consideration of approximately US$510 million. The placing agent in the transaction was Morgan Stanley. The transaction was announced on January 17, 2023 and closed on January 19, 2023. The Fangda team on this deal was led by partners Colin Law and Arman Lie, counsel Jonathan Wallenberger, associates Karen Chan and Jennifer Mok. Fangda advised on the transaction and prepared for the disclosure and other related documents. This transaction is the seventeenth placement since listing in 2017. The aggregate value of all placement transactions of the Company amounted to approximately US$12.5 billion.
Join our mailing list for legal news and alerts
Sign up